Arrowhead Pharmaceuticals Inc (ARWR)
Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China
Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China
📈 **POSITIVE** • High confidence analysis (82%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business